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Abstract
AIM
To assess the accuracy of shear wave elastography 
(SWE) alone and in combination with aminotransferase 
platelet ratio index (APRI) score in the staging of liver 
fibrosis.
METHODS
A multicenter prospective study was conducted to 
assess the accuracy of SWE (medians) and APRI to 
predict biopsy results. The analysis focused on distingui-
shing the different stages of liver disease, namely, F0 
from F1-4, F0-1 from F2-4, F0-2 from F3-4 and F0-3 
from F4; F0-F1 from F2-F4 being of primary interest. 
The area under the receiver operating characteristic 
(AUROC) curve was computed using logistic regression 
model. The role of age, gender and steatosis was also 
assessed.
RESULTS
SWE alone accurately distinguished F0-1 from F2-4 with 
a high probability. The AUROC using SWE alone was 
0.91 compared to 0.78 for using the APRI score alone. 
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The APRI score, when used in conjunction with SWE, 
did not make a significant contribution to the AUROC. 
SWE and steatosis were the only significant predictors 
that differentiated F0-1 from F2-4 with an AUROC of 
0.944.
CONCLUSION
Our study validates the use of SWE in the diagnosis and 
staging of liver fibrosis. Furthermore, the probability of 
a correct diagnosis is significantly enhanced with the 
addition of steatosis as a prognostic factor.
Key words: Shear wave elastography; Aminotransferase 
platelet ration; Liver fibrosis; Liver biopsy
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The gold standard in the diagnosis and staging 
of liver fibrosis is an invasive liver biopsy. The accuracy 
of non-invasive tools such as ultrasound shear wave 
elastography either alone or in combination with the 
use of the aspartate transaminase platelet ratio index 
score compared to histology to guide management of 
liver fibrosis is not known. We addressed this question 
in a multicenter trial in patients with chronic progressive 
liver disease in a low to middle income country.
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INTRODUCTION
Liver fibrosis is a progressive condition that if diagnosed 
early and staged accurately, allows early clinical inter­
vention that may arrest or slow down progression to 
end stage decompensated cirrhosis. The spectrum of 
chronic liver disease and fibrosis that leads to end stage 
decompensated cirrhosis, is an important cause of 
morbidity and mortality in the world[1]. Early diagnosis, 
accurate staging and re­evaluation of liver fibrosis is aimed 
at avoiding the progression from normal to minimal to 
significant fibrosis and timely management of patients 
with advanced disease. 
There are several chronic progressive liver diseases 
that lead to liver fibrosis. Non­alcoholic fatty liver 
disease (NAFLD) is one of the most common. NAFLD is 
closely associated with obesity and insulin resistance. 
Pathological changes in the biochemical profile of the 
liver that lead to liver fibrosis also occur due to chronic 
metabolic conditions such as diabetes and degenerative 
conditions like atherosclerosis[2,3]. Other common causes 
of liver fibrosis include infections such as chronic viral 
hepatitis and human immunodeficiency virus. Drugs 
and other toxins also play an important role. This list 
is not exhaustive but this paper focuses on the last 
four causes. Liver fibrosis is characterized by excessive 
accumulation of extracellular matrix due to the release 
of inflammatory mediators and free radicals to cause 
oxidative stress and liver fibrogenesis. During this process 
hepatic stellate cells activation occurs. Platelet derived 
growth factor, tumor necrosis factor α, transforming 
growth factor β or reactive oxygen species play a role 
in the progression to liver fibrosis. Several phenotypic 
alterations occur with the end result being irreversible[4]. 
The current gold standard in the diagnosis and staging 
of liver fibrosis is liver biopsy. Liver biopsy and more 
recently ultrasound guided liver biopsy only evaluates 
1/50000 of the liver parenchyma. It is invasive, has 
a complication rate (albeit small,) and is subject to 
intra and inter­observer variability[5]. Because of the 
imperfect nature of liver biopsies, over the last several 
years there has been a growing trend to validate non­
invasive tools to diagnose and stage liver fibrosis. 
Alkaline aminotransferase platelet ratio index (APRI) 
is a laboratory marker that has been shown to have 
some value but is inferior to liver biopsy. Ultrasound 
and magnetic resonance have been used for elasticity 
imaging. Magnetic resonance elastography, even though 
promising, has some disadvantages. Aside from the 
significant cost of the study, it cannot be performed 
in a liver with iron overload because of signal­to­noise 
limitations; has longer examination times compared to 
ultrasound elastography, and is subject to respiratory 
artifact[6]. Ultrasound elastography has been validated 
and has been shown in many studies to have similar 
sensitivity and specificity to liver biopsies[5,7]. 
Ultrasound elastography measures the liver stiffness/
elasticity by assessing at least 100 times the proportion 
of the liver that a biopsy does. Transient elastography 
(TE) has been validated in multiple studies[8] but 
shear wave elastography (SWE) may be preferred 
because unlike transient elastography, which consists 
of a vibrator producing shear waves, the latter can 
perform a conventional ultrasound at the same time. 
The technique is integrated into an ultrasound system. 
The principle behind the interpretation of shear wave 
elastography is that shear waves produced by a focused 
ultrasound beam are directly related to the stiffness 
of the liver from where they are generated[5,7,8]. SWE 
is also reportedly more accurate than TE in assessing 
significant fibrosis (≥ F2)[8,9]. The use of shear wave 
elastography in the diagnosis and staging of liver fibrosis 
has been increasing. Being a non­invasive technique 
proves advantageous because repeat measurements 
can be obtained in patients with chronic progressive 
liver diseases. However, this non­invasive procedure 
does have some pitfalls. It is subject to intra­ and inter­
observer variability, validated cut­offs have mainly 
only been demonstrated in hepatitis C; Acute hepatitis 
can have false positives. In patients with a high body 
mass index, erroneous values may be obtained. A very 
practical pitfall is confounding factors such as edema, 
inflammation, cholestasis and congestion. All these 
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must be put in context and a multidisciplinary clinical 
approach used in the interpretation of the results[5,7,8,10].
A limitation of prior studies is the lack of integration 
of the accuracy and limitations of elastography. No prior 
study has combined elastography with the use of APRI 
and histology to guide management of liver fibrosis. 
This study addresses the gaps and makes practical 
inferences that focus on accurate early diagnosis and 
staging. The focus in our study is “interpretation within a 
clinical context”. This multi­institutional study performed 
in Kenya aims to capture and highlight factors based 
on the disease burden in this region. Ultrasound elasto­
graphy has only recently been made available in East 
Africa. The findings, therefore, could be of wider benefit 
because of the high burden of other etiologies of liver 
disease such as hepatitis B in the region. Most studies 
thus far have been carried out in the West with the 
disease burden focused on hepatitis C. In addition, 
the literature largely reports data from middle­high 
economic areas whereas adherence to clinical guidelines 
may not be as feasible in poor/resource challenged 
facilities. 
MATERIALS AND METHODS
Objectives
The primary objective was to analyze the accuracy of 
shear wave elastography in comparison to liver biopsy 
in differentiating the various stages of liver fibrosis. The 
secondary objective was to evaluate whether the addition 
of the APRI score to SWE would improve the accuracy 
of this differentiation. With these, illustrate the role of 
the shear wave elastography, APRI score, and biopsy 
solely and or in combination in the diagnostic algorithm 
of accurate quantification of liver fibrosis. We also sought 
to assess the role of other covariates, namely, age, 
gender and steatosis, and their influence on the relative 
importance of SWE and the APRI score in predicting the 
extent of liver fibrosis.
Design 
Three hospitals were included in this prospective study: 
Aga Khan University (AKU) Hospital, Kenyatta Teaching 
and Referral Hospital and St Mary’s Mission Hospital. 
Approval was obtained from the relevant Scientific and 
Ethics committees. All consecutive patients referred for 
an ultrasound guided liver biopsy at all three institutions 
were subject to recruitment based on the inclusion and 
exclusion criteria as well as informed written consent. 
The study included patients above eighteen years of age 
with chronic progressive diffuse liver disease. Patients 
were excluded from the study if they did not have any of 
the three diagnostic tests, i.e., liver biopsy, APRI score or 
SWE. 
Consecutive patients were recruited by the principle 
investigator in three ways: (1) referral for an ultrasound 
guided liver biopsy at the AKU Radiology Department; (2) 
referral from St Mary’s Hospital with biopsy performed 
by the AKU Radiology department and pathological 
analysis performed at AKU department; and (3) referral 
for a liver biopsy request to be analyzed at the Pathology 
department of Kenyatta National Hospital.
At recruitment, a study file was opened for each 
patient by the principle investigator at the AKU. Routine 
liver function tests, platelet counts, and demographic 
information related to confounding factors of chronic 
liver disease, including information on alcohol use, 
Human Immunodeficiency Virus status, viral load and 
CD4 levels, hepatitis B and C status was collected.  Men 
who had been drinking more than 30 g of alcohol per 
day and women who had been drinking more than 20 g 
of alcohol per day were considered current drinkers. 
Patients who had stopped drinking completely for more 
than six months before the biopsy were considered ex­
drinkers[11].
At the AKU routine ultrasound of the liver was per­
formed to qualitatively record presence (grade 0­3) or 
absence of steatosis using established criteria published 
by Lupşor­Platon et al[12]. Any other diffuse or focal 
lesions were documented followed by SWE. At AKU 
elastography measurements were taken from the 
right lobe[13] of the liver with the patients holding their 
breath. Measurements were considered successful 
using validated criteria established by Castéra et al[14]: 
“(1) 10 valid shots; (2) a ratio of valid shots to the total 
number of shots of 60% or higher; and (3) variability 
of measurements less than 30% of the median value 
of liver stiffness measurements”. Philips iU22 ultra­
sound machine with its C5­1 curvilinear transducer 
was used. The units for SWE readouts (liver stiffness) 
were kilopascals (kPa). Four sonologists each with more 
than 5 years’ experience in routine liver scanning and 
validated ultrasound elastography experience from 
uniform training performed each exam independently. The 
median stiffness (used to grade the fibrosis), average 
stiffness and standard deviation of measurements 
generated by the software were recorded and inter­
preted by the four sonologists independently[7,10]. Each 
patient had one liver biopsy specimen taken from the 
right lobe[13] after the ultrasound elastography which 
was graded histologically for fibrosis based on the 
Metavir classification system[15,16]. This was done by 
two experienced histopathologists at the AKU and KNH 
Pathology departments. Each specimen was evaluated by 
the two histopathologists from each respective pathology 
department. Discrepancies were resolved by consensus 
between the two. The histopathologists from the two 
sites were full­time faculty, certified by the Kenya Medical 
Practitioners and Dentists Board, practicing in University 
Hospitals each with greater than ten years’ experience 
in liver biopsy assessment for fibrosis. In each patient 
the time interval between ultrasound, elastography 
and histology was not more than one month. The path­
ologists and sonologists were blinded to clinical data and 
elastography or histology grade.
Interpretation of liver fibrosis by shear wave elasto­
graphy in kPa divided the entity into no fibrosis (F0), mild 
fibrosis (F1), severe fibrosis (F2), significant fibrosis (F3) 
Sande JA et al . Ultrasound shear wave elastography and liver fibrosis
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and cirrhosis (F4). Automatic median value generated 
by the ultrasound software was used to establish the 
elastography grade as follows < 4.6 = F0, 4.6­5.6 = F1, 
5.7­7.0 = F2, 7.1­12.0 = F3 and > 12 = F4[10,17­19]. APRI 
score was calculated using a formula proposed by original 
study of Wai et al[20]: APRI = [(AST level/ULN)/platelet 
counts (109/L)] × 100. A score of < 0.5 was graded as 
F0, 0.5­1.5 as F1­3 and > 1.5 as F4. The corresponding 
histology grade was assessed[21,22].
Sample size estimates
The sample size was determined with the aim to keep 
the standard error of the AUROC at 0.05. This set the 
difference between the upper and lower 95%CI limits to 
0.20 (± 2 standard errors). From previous publications 
the range for the AUROC for significant fibrosis, as deter­
mined from non­invasive tests, is approximately 0.69 to 
0.89; for cirrhosis the range is from 0.81 to 0.98. Assum­
ing the AUROC to be approximately 0.8[20] the sample 
size of 110 patients would yield a standard error of 0.05 
(Table 1). 
Shear wave elastography has been shown to have 
a lower operator error technique than transient elasto­
graphy (3%­16%)[23­25]. As a precautionary measure we 
raised the sample size from 110 to 130.
Statistical analysis
The statistical review of the study was performed by 
a biomedical statistician. Logistic regression models 
with backward elimination, using SAS version 9.3, 
were utilized to assess the significance of SWE median, 
the APRI score and the covariates age (categorized as 
below and above the median), gender and steatosis. 
Besides the P­values, the analysis provided the ORs 
and their respective 95%CI limits. The sensitivity and 
the specificity were computed based on the variables 
included in the model. This in turn enabled the ROCs 
and the AUROC to be determined. Summary statistics 
and correlation coefficients, where appropriate, were 
computed.
RESULTS
Demographics and baseline characteristics
One hundred and twenty­eight patients were recruited 
for the study. AKU, KNH and St. Mary’s contributed 
54 (42.2%), 53 (41.4%) and 21 (16.4%) patients, re­
spectively. The most prevalent viral infection was hepatitis 
B that was noted in 30 (23.4%) patients. This was 
followed by human immunodeficiency virus (HIV) with 
18 (14.1%) and hepatitis C with 13 (10.2%) patients 
(Appendix 1); fifteen patients had 2 or more infections. 
Sixty­three (49.2%) of the patients had a steatosis score 
of 0 and 61 (47.7%) of the patients had a histology 
fibrosis score of 0. Eighty­one (63.3%) patients fell in the 
histology fibrosis score subgroup F0­1; the remaining 47 
(36.7%) fell in the F2­F4 subgroup. Fifty percent of the 
patients had an elastography score of F0 and 59 (46%) 
of the patients the APRI score of F0 (Appendix 2). The 
elastography median scores were the lowest among 
HIV subjects followed by those with hepatitis B and then 
a hepatitis C infection. The highest scores were from 
those with multiple viral infections. The APRI scores also 
follow the pattern described above for the elastography 
median scores (Appendix 3). There appears to be a 
good correlation between the elastography median 
scores and the histology fibrosis scores (Appendix 4). 
The elastography and APRI fibrosis score are statistically 
significantly correlated with the histology fibrosis scores 
(Appendix 5) (Figure 1 and Table 2).
Logistics regression results 
Table 3 summarizes some of the key results that stem­
med from the analysis of the SWE median and APRI 
score data using logistic regression. Both variables show 
a high degree of statistical significance in their individual 
ability to distinguish between the lower stages of fibrosis 
compared to the higher stages. This is true across all 
possible partitions of the Metavir fibrosis scores. However, 
the AUROCs for SWE medians are much higher than 
35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Summary of elastography average
Mean 3.4 4.5 6.4 9.0 15.1
Min 0.5 1.3 3.2 5.2 2.2
Max 5.8 6.2 14.4 12.7 34.5
El
as
to
gr
ap
hy
 a
ve
ra
ge
Histology fibrosis scores
0                1                2                3                4
Figure 1  Elastography average vs histology fibrosis score (Box Plot).
AUROC Total (n ) % Positive # Positive # Negative SE Confidence interval
Lower Upper
0.8 110 30 33 77 0.050 0.701 0.899
0.8 130 30 39 91 0.046 0.709 0.891
Table 1  Summary illustrating sample size calculation above
AUROC: Area under the receiver operating characteristic. 
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those for APRI score.
The SWE median differentiates the Metavir fibrosis 
subgroups F0­1 and F2­4 with an AUROC of 0.908 
compared to 0.780 for the APRI score. These results 
imply that the SWE on its own is a better predictor of the 
differentiating the subgroups than the APRI score. When 
we utilize both variables simultaneously, the increase 
in the AUROC attributed to the APRI score is less than 
1.2% higher than that predicted by SWE median. This 
amounts to about 13% of the 9% not predicted correctly 
by the SWE median. The results for other partitions of 
the histology fibrosis scores mimic those described above 
with the AUROC for SWE median being around 0.9 and 
that of the APRI score being about 0.8.
Additional logistic regression models incorporated 
several other variables in the analysis to evaluate their 
impact on the AUROC. The variables considered, in 
addition to the SWE median and the APRI score were 
the covariates age (categorized as below and above 
the median), gender and steatosis score. The results of 
the logistic regression analysis (Table 4) with all of the 
aforementioned variables in the model showed that SWE 
and the steatosis score were the only two variables that 
made significant contributions to the predictive power of 
the model.
Using the backward elimination method, all of the 
variables that were not making a significant contribution 
at the 0.1 level were dropped from the model. The 
results of these analysis (Table 5) show that for the 
primary objective of differentiating between F0­1 and 
F2­4 is accomplished quite well with an AUROC of 0.944; 
the two variables that made a significant contribution 
were SWE and steatosis. The steatosis score adds 
significantly to the prediction model that tries to identify 
the fibrosis group that a patient belongs to (Table 5); 
this is true in every case except for the F0­3 vs F4 
partition. The APRI score on the other hand makes a 
significant contribution to only the partition F0­2 vs F3­4. 
Given that the APRI score appears in only one partition 
as an important predictor, an additional analysis was 
performed by dropping the APRI score from the model. 
This resulted in adding a few additional observations to 
the data set used for analysis since missing APRI scores 
had contributed to a slightly reduced sample size. In 
addition, the steatosis score was added to the F0­3 vs F4 
model in order to have a unique set of predictors across 
Histology fibrosis scores Total χ 2
0 (n  = 61) 1 (n  = 20) 2 (n  = 20) 3 (n  = 10) 4 (n  = 17) (n  = 128) P  value
Elastography fibrosis score 
   F0 51 (83.6)   7 (35.0)   5 (25.0) 0 (0.0) 1 (5.9)   64 (50.0) < 0.0001 
   F1 10 (16.4) 10 (50.0)   2 (10.0)   2 (20.0) 1 (5.9)   25 (19.5) 
   F2 0 (0.0)   3 (15.0)   9 (45.0)   1 (10.0) 0 (0.0)   13 (10.2) 
   F3 0 (0.0) 0 (0.0)   3 (15.0)   7 (70.0) 1 (5.9) 11 (8.6) 
   F4 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0) 14 (82.4)   15 (11.7) 
APRI fibrosis score          
   0 45 (73.8)   6 (30.0)   6 (30.0)   1 (10.0) 1 (5.9)   59 (46.1) < 0.0001 
   1 to 3 14 (23.0) 13 (65.0)   9 (45.0)   9 (90.0)   8 (47.1)   53 (41.4) 
   4 2 (3.3) 1 (5.0)   5 (25.0) 0 (0.0)   8 (47.1)   16 (12.5) 
Steatosis             
   Grade 0 48 (78.7)   8 (40.0)   2 (10.0)   1 (10.0)   4 (23.5)   63 (49.2) < 0.0001 
   Grade 1 6 (9.8)   8 (40.0)   5 (25.0)   1 (10.0) 1 (5.9)   21 (16.4) 
   Grade 2 6 (9.8)   2 (10.0)   7 (35.0)   4 (40.0) 0 (0.0)   19 (14.8) 
   Grade 3 1 (1.6)   2 (10.0)   6 (30.0)   4 (40.0) 12 (70.6)   25 (19.5) 
Table 2  Summary of liver disease scores by histology fibrosis score (discrete variables)  n  (%)
APRI: Aminotransferase platelet ratio index.
Sande JA et al . Ultrasound shear wave elastography and liver fibrosis
F0-3 vs  F4 F0-2 vs  F3-4 F0-1 vs  F2-4 F0 vs  F1-4
SWE median P value < 0.0001 < 0.0001 < 0.0001 < 0.0001
OR  1.708  1.789  2.983  2.683
95%CI 1.379, 2.115 1.432, 2.236 1.839, 4.838 1.789, 4.025
AUROC  0.926  0.929  0.908  0.879
APRI score P value    0.0202  0.039    0.0005    0.0008
OR  1.511  1.404  3.482  4.651
95%CI 1.067, 2.141 1.018, 1.938 1.727, 7.018 1.895, 11.416
AUROC  0.812  0.784  0.780  0.803
SWE and APRI1 AUROC  0.927  0.931  0.920  0.890
APRI influence  0.001  0.002  0.012  0.011
1SWE median and APRI score. OR: Odds ratio; SWE: Shear wave elastography; APRI: Aminotransferase platelet ratio index; AUROC: Area under the 
receiver operating characteristic. 
Table 3  Shear wave elastography median and aminotransferase platelet ratio index score to differentiate between metavir subgroups
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all partitions. These results are presented in Table 6. The 
fact that the results from Tables 5 and 6 are very similar 
implies that the missing data points did not influence the 
outcome in any meaningful way.
The F0­2 vs F3­4 data shows that the AUROC ob­
tained with the use of the SWE median and the steatosis 
score is 0.954 (Table 6). By adding the APRI score 
(Table 5) the AUROC increase of 0.008 or 0.8%.  This 
represents a decrease of about 13% (0.008 of 0.046) 
in the error rate. On the other hand, adding steatosis to 
the model after including the SWE median and the APRI 
score, the AUROC increase from 0.931 (Table 3) to 0.962 
(Table 5), an increase of 0.031 or 3.1%. This represents 
a decrease of about 44.9% (0.031 of 0.069) in the error 
rate. 
DISCUSSION
Summary of findings
The infection with the highest prevalence was hepatitis 
B. There were also patients with HIV, hepatitis C and 
the co­infections in this cohort. While the prevalence of 
hepatitis B, C and HIV in Sub­Saharan Africa has not 
been conclusively established[26], it has been postulated 
that hepatitis B is relatively more prevalent than hepatitis 
C as compared to the western world where hepatitis 
C is more prevalent[27]. Most studies on liver fibrosis 
quantification have been carried out in the western world 
therefore it is important to have the same studies carried 
out in Sub­Saharan Africa where the epidemiology of the 
viral infections is likely to be different. The elastography 
median scores were the lowest among HIV subjects 
followed by those with hepatitis B infection; the next 
highest score was for patients with a hepatitis C infection. 
The lowest score was from those with multiple infections. 
The APRI scores also follow the pattern described above 
for the elastography scores. This pattern corresponds 
with what has previously been described. Hepatitis C 
most likely has higher levels of quantified liver fibrosis 
because of the three viruses it has the most indolent 
and chronic clinical course. The mortality from these 
infections is correlated to chronic liver disease and not 
due to progression of the virus due to the success of 
antiretroviral therapy[27,28].
Analysis categorized fibrosis as, F0 vs F1­4, F0­1 vs 
F2­4, F0­2 vs F3­4, F0­3 vs F4. The results focus on F0­1 
vs F2­4 which is of most clinical significance (no and non­
significant fibrosis vs significant fibrosis that demands 
intervention). There is a good correlation between the 
elastography median scores and the histology fibrosis 
scores. The OR of 3.0 implies that the elastography 
median scores are 3 times more likely to correctly identify 
a fibrosis score of F2­4 compared to F0­1. The upper and 
lower limits for the OR with 95%CI do not cross 1 which 
Variable  DF Coefficient 
estimate 
Standard 
error 
Wald χ 2 Pr > χ 2 OR estimate Lower 95%CI limit 
for OR 
Upper 95%CI limit 
for OR 
Intercept 1 -6.6482 1.3510 24.2158 < 0.0001
Age category LE median 1  0.0971 0.3219   0.0910    0.7629 1.214 0.344 4.288
APRI score 1  0.1946 0.3873   0.2526    0.6153 1.215 0.569 2.595
Elastography median 1  0.9041 0.2513 12.9464    0.0003 2.470 1.509 4.042
Sex Female 1  0.3330 0.3551   0.8797    0.3483 1.947 0.484 7.830
Steatosis 1  1.1317 0.3462 10.6843    0.0011 3.101 1.573 6.112
Table 4  Prediction of histology fibrosis score (Grouping: F0-1 vs  F2-4) using elastography median, aminotransferase platelet ratio 
index score, age category1, sex and steatosis maximum likelihood and odds ratio estimates
1Age category (years): n = 128. Mean (SD) 46 (16.99). Median 42; Minimum 18; Maximum 108. OR: Odds ratio; APRI: Aminotransferase platelet ratio index.
F0-3 vs  F4 F0-2 vs  F3-4 F0-1 vs  F2-4 F0 vs  F1-4
SWE median < 0.0001 < 0.0001   0.0003   0.0002
APRI score NS1     0.0404 NS NS
Age NS NS NS NS
Gender NS NS NS NS
Steatosis NS     0.0263   0.0002   0.0007
AUROC   0.926   0.962 0.944 0.902
Table 5  Significance of predictive values associated with key 
pre-identified variables
1NS: Not significant at the 0.1 level. SWE: Shear wave elastography; APRI: 
Aminotransferase platelet ratio index; AUROC: Area under the receiver 
operating characteristic. 
Variable Pr > χ 2 OR 
estimate
Lower 95%CI 
limit for OR 
Upper 95%CI 
limit for OR 
F0-3 vs F4
   Intercept < 0.0001
   Elastography median < 0.0001 1.681 1.347 2.099
   Steatosis 0.6529 1.187 0.563 2.502
   AUROC = 0.936
F0-2 vs F3-4
   Intercept < 0.0001
   Elastography median < 0.0001 1.684 1.353 2.097
   Steatosis 0.0568 1.846 0.982 3.467
   AUROC = 0.954
F0-1 vs F2-4
   Intercept < 0.0001
   Elastography median 0.0003 2.397 1.500 3.828
   Steatosis 0.0002 3.135 1.703 5.772
   AUROC = 0.944
F0 vs F1-4
   Intercept < 0.0001
   Elastography median 0.0002 2.221 1.463 3.370
   Steatosis 0.0007 2.496 1.473 4.230
   AUROC = 0.902
Table 6  Elastography median and steatosis
OR: Odds ratio; AUROC: Area under the receiver operating characteristic. 
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strengthens this result. However, the limits are wide 
1.8­5. This may be due to the small sample size and 
because close to 50% of the sample at F0. If F0 were 
to be eliminated from the analysis this may reduce the 
limits with a questionable effect on clinical significance. 
The accuracy of the elastography median depends on 
the sensitivity and specificity. This is clear from the raw 
data used to generate the ROC curve. An elastography 
median of approximately 3.8 is the point at which you 
get the best sensitivity matched with specificity. The ROC 
curve for model, which depicts sensitivity and specificity, 
illustrates how for a very high sensitivity, specificity is low 
and as sensitivity reduces; one arrives at a point where 
specificity is acceptable clinically. That is, one can identify 
disease with a high sensitivity and be correct (specifically 
know that you are also picking the non­diseased). The 
AUROC for the elastography median was 0.91. The 
elastography and APRI fibrosis score are statistically 
significantly correlated with the histology fibrosis scores. 
However, APRI score in itself or when combined with 
elastography median score does not significantly increase 
the accuracy of elastography in the differentiation of non­
significant vs significant fibrosis. APRI had an AUROC 
of 0.78. APRI and elastography median had an AUROC 
of 0.92. Therefore APRI does not have a statistically 
significant effect on the prediction of F0­1 from F2­4 
when added to elastography. And when used alone it is 
significantly less accurate than elastography. However in 
patients with chronic progressive liver fibrosis who need 
repeated analysis to categorize and monitor the progress 
of liver fibrosis APRI does have a clinically significant role 
in the management algorithm of liver fibrosis.
Previous studies vary on the accuracy of elastography. 
The sensitivity, specificity and diagnostic accuracy of 
shear wave elastography in the determination of liver 
stiffness compared with biopsy results is comparable 
to[8­10]. The accuracy of elastography mirrors those 
depicted by these studies albeit a slightly higher accu­
racy in this study. This may be due to the difference in 
grouping of the fibrosis scores for analysis. Also, if the 
F0 of this study are removed from the analyses this 
may lead to more similar figures since the F0 constitute 
approximately 50%. The diagnostic accuracy of shear 
wave elastography and APRI score in the determination 
of liver stiffness has not been reported before[8­10].
Ordinal regression and backward elimination was 
used to analyze significance of HIV, hepatitis B, alcohol 
use, steatosis, age and gender. It showed that steatosis 
has a significant OR and P­value in the analysis for 
fibrosis. Ferraioli et al[10] showed that steatosis does not 
affect the performance of elastography. The challenge as 
stated in this paper is the confounding effect of various 
pathologies in the diagnosis and staging of liver fibrosis. 
This is particularly relevant in the generation and given 
the wide use of reference ranges for all modalities 
used in the diagnosis and staging of liver fibrosis. It is 
for this reason that to date several studies have used 
variable reference ranges for F0­F4[8,10,17­19]. Our results 
highlight the potential effect of the presence of steatosis 
(EF­S_1_10_3_Logistic_All Variables_F0­F1VsF2­F4 
document) on the diagnosis and characterization of liver 
fibrosis. Of note from this result is the increase in the 
AUROC from 0.91 (Figure 2) to 0.95 (Figure 3) in the 
logistic regression backward elimination analysis that 
is attributable to the elastography median and steatosis 
each with a significant P­value and OR (Table 4). This is an 
area that needs further study, especially since steatosis 
was measured subjectively in this study. The data on 
HIV and alcohol use as variables were not adequately 
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Figure 2  Prediction of histology fibrosis score (Grouping: F0-F1 vs F2-F4) 
using elastography median. ROC: Receiver operating characteristic.
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Figure 3  Prediction of histology fibrosis score (Grouping: F0-1 vs F2-4) 
using elastography median, aminotransferase platelet ratio index score, 
age categor, sex and steatosis. 
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powered to add to this analysis.
Strengths  
This study is timely because of the growing use of elas­
tography in the developed world. In the developing 
world the use of this diagnostic tool needs to grow via 
an evidence based approach that is tailored to the local 
disease burden. Most research in the west has focused 
on hepatitis C and alcohol or nonalcoholic steatosis. The 
wider disease burden covered in this study is thus a 
more homogenous representation of chronic liver fibrosis 
pathology. The complimentary use of APRI score is 
especially relevant in resource limited setups.
Theoretical and practical implications of these findings
This study brought to light theoretical implication of the 
need to standardize the diagnosis and accurate staging 
and follow­up of liver fibrosis. Figure 4 depicts the link 
between all tests used in the evaluation of liver fibrosis 
(Figure 4).
The use of all tests should be complimentary and 
histology has its place but the noninvasive tests may be 
more logical in the beginning and for progressive moni­
toring. Inference from the results generates a flowchart 
below describing a management algorithm (Figure 5).
Inference from the results: Consider the following 
flowchart at diagnosis
Practical unique and reported challenges exist. Care 
needs to be taken in interpretation and training for elasto­
graphy. Technical and interpretation skill for elastography 
specifically when choosing the ten values to include in 
the report; this includes excluding/ignoring far outliers, 
though these outliers may represent focal areas of diffe­
rent fibrotic stages! Use of the median to give a final 
conclusion of the ten chosen readings is appropriate 
especially in the setting of variable readings. But, care 
must be exercised. There should be a low threshold to 
recommend a biopsy (still the gold standard) to confirm 
the findings especially if the mean elastography reading is 
in keeping with a diagnosis of no fibrosis yet the standard 
deviation is high in the presence of individual readings of 
cirrhosis[5]. The challenge of the heterogeneously fibrotic 
liver or presence of lesions, e.g., metastasis causing 
heterogeneity of the liver rendering fibrosis assess­
ment questionable in terms of using just the median to 
conclude on the level of fibrosis especially when there 
is a big difference in the individual stiffness values must 
be remembered. These issues red flag the danger of not 
allowing room to vary an impression and advise further 
evaluation with an United States guided liver biopsy to 
correlate[5]. Indeed, one must also bear in mind that 
the suggestion to further evaluate with a liver biopsy is 
inherently flawed because of the attend pitfalls of the 
tool. Chronic progressive liver fibrosis needs accurate 
early diagnosis and interval monitoring. Elastography is 
a validated tool. APRI can be used as a complimentary 
tool though its effect is not of statistical significance but 
clinical significance. Biopsy remains the gold standard. 
We propose a flow chart at diagnosis. Further, the pro­
bability of a correct diagnosis is significantly enhanced 
with the addition of steatosis as a prognostic factor (Figure 5).
Limitations and problems encountered in the method
The number of ultrasound guided liver biopsies for the 
assessment of liver fibrosis has continued to reduce 
because of the increasing use of elastography which is 
noninvasive and without the side effects associated with 
Liver fibrosis
US elastography
Diagnosisand 
monitoring
US guided liver 
biopsy. Diagnosis
APRI score.
Coplimentary 
monitoring
Figure 4  Link between diagnostic tests used in the evaluation of liver 
fibrosis. US: Ultrasound; APRI: Aminotransferase platelet ratio index.
Begin with ultrasound elastography result
< F2 > F2
Follow-up clinically plus with, APRI 
and elastrography
Biopsy for baseline of chronic 
progressive condition,
decide on whether to intervene 
or not
When elastrography > F2, Biopsy
Follow clinically plus with, APRI 
and elastrography
Biopsy again to reestablish 
baseline or when considering 
change in intervention
Figure 5  Flow chart depicting use of diagnostic tests in liver fibrosis. Begin 
with US SWE result. US: Ultrasound; SWE: Shear wave elastography; APRI: 
Aminotransferase platelet ratio index.
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liver biopsy. This diagnostic trend is reinforced by the 
continued validation of elastography[5,7,10,12]. Therefore 
during this study the recruitment rate was low. As such 
participants were recruited from three different sites to 
meet the sample size requirement to adequately power 
the results. The ultrasound and elastography where all 
performed at the same site (AKU). Biopsy results were 
analyzed by pathologists at two of the three sites (AKU 
and KNH). This may have potentially led to variable 
histological inter­observer variability. To counter this 
each sample was read by each pathologist at each 
respective site and discrepant values were resolved 
by consensus. However, major and minor discrepancy 
analyses of histology for inter­observer discrepancies 
were not assessed. 
There are limitations associated with elastography, 
including the confounding effects of inflammatory activity, 
and to a lesser extent, steatosis[13], on liver stiffness 
evaluation. There is also reduced accuracy observed 
in lower fibrosis stages (F0­F2). Furthermore, the inci­
dences of failed and unreliable scans have been reported 
to be approximately 3% to 16% in transient elastography 
but less in shear wave elastography (figures not reported 
yet)[22]. The sample size was inflated by 5% to cater for 
this. A typical liver biopsy covers 1/10000th of the liver 
while elastography covers a larger area. Matching the 
two sites covered by the two exams may not have been 
100%.
The information sort in the data collection form to 
analyze the secondary objectives was sensitive in nature 
including queries about alcohol use and HIV status. This 
precluded complete disclosure from participants and led 
to inadequate data on related parameters. This led to a 
reduction in the power of inferences regarding the role 
of alcohol and HIV.
Suggestions for improvement and further work
This has been an East African experience: Unique cha­
llenges and similar differences to those published. More 
comprehensive analysis needs to be done to further 
reveal the extent of confounding factors affecting the 
use of elastography in the diagnosis and staging of liver 
fibrosis. The role of steatosis needs further objective 
assessment. Further work needs to be done to describe 
the in cooperation of magnetic resonance elastography in 
the diagnostic algorithm of liver fibrosis.
Our study validates the use of ultrasound shear wave 
elastography in the diagnosis and staging of fibrosis 
within the context of liver disease in a LMIC. 
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Background
Chronic progressive liver diseases cause liver fibrosis whose end result is 
decompensated liver failure. Liver fibrosis that results from these diseases can 
be reversed if diagnosed early. The current gold standard in the diagnosis of 
liver fibrosis is a liver biopsy preferably ultrasound guided, which is an invasive 
procedure with limitations and risks. Recent research have validated the use of 
shear wave ultrasound based liver elastography which is a non-invasive imaging 
based tool that has a sensitivity and specificity that almost parallels histological 
diagnosis from a liver biopsy. The staging of liver fibrosis at diagnosis uses a 
Metavir scoring system that has been adapted by elastography. Aminotransferase 
to platelet ratio index is a liver function test that has some usefulness in the 
diagnosis of liver fibrosis. The combined use of histology, elastography and 
aminotransferase to platelet ratio index has not been elucidated.
Research frontiers
Previous studies have shown that ultrasound based elastography can substitute 
liver biopsy in the accurate diagnosis of liver fibrosis.
Innovations and breakthroughs
This is the first study to evaluate the combined role of ultrasound based 
elastography, histology and aminotransferase to platelet ratio index in a low to 
middle income country for the management of progressive liver fibrosis.
Applications
The use of the three tests should be complimentary and histology has its 
place but the noninvasive tests may be more logical in the beginning and for 
progressive monitoring. More comprehensive analysis needs to be done to further 
reveal the extent of confounding factors affecting the use of elastography in the 
diagnosis and staging of liver fibrosis. Further work needs to be done to describe 
the in cooperation of magnetic resonance elastography in the diagnostic algorithm 
of liver fibrosis.
Terminology
Elastography is radiological based software that can diagnose and quantify the 
degree of liver fibrosis. It is either ultrasound or magnetic resonance based. 
Ultrasound bases elastography uses sound have to assess for and quantify 
liver stiffness that is directly related to liver fibrosis. Aminotransferase to platelet 
ratio is a laboratory parameter derived from part of the routine liver function 
tests and platelet count.
Peer-review
The authors have validated the use of ultrasound shear wave elastography in 
the diagnosis and staging of fibrosis within the context of liver disease in a low to 
middle income country. Practical management algorithms that in cooperate the 
use of ultrasound based elastography, histology and aminotransferase to platelet 
ratio index have been demonstrated. More comprehensive analysis needs to 
be done to further reveal the extent of confounding factors affecting the use of 
ultrasound or magnetic resonance based elastography.
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